U.S. flag An official website of the United States government
  1. Home
  2. For Consumers
  3. Consumer Information by Audience
  4. Minority Health and Health Equity
  5. An Epigenome-Wide Association Study (EWAS) of Peripheral Blood Mononuclear Cells from African American and European American Women With and Without Lupus
  1. Minority Health and Health Equity

An Epigenome-Wide Association Study (EWAS) of Peripheral Blood Mononuclear Cells from African American and European American Women With and Without Lupus

Principal Investigator: Beverly D. Lyn-Cook

FDA Center: National Center for Toxicological Research, FDA (2014)


Why It's Important

Lupus affects African American women more often than European American women. FDA approved Lupus drug Benlysta in 2011, however the drug performed better on European American women. Therefore this study investigates a potential molecular basis for why the drug may have performed better in European American women than African American women.


About the Project

FDA approved a drug to treat Systemic Lupus Erythematous (Lupus) in 2011. African American women are at least twice as likely to have Lupus as European American women. The researchers investigated a potential mechanism that may inform why the drug did not work as well for African American women.


Expression Levels of BAFF, APRIL, and Their Receptors in Peripheral Blood Mononuclear Cells of European and African-American Women with Systemic Lupus Erythematosus

Research poster for Epigenome-Wide Association Study (EWAS) of Peripheral Blood Mononuclear Cells from African American and European American Women With and Without Lupus

Expression Levels of BAFF, APRIL, and Their Receptors in Peripheral Blood Mononuclear Cells of European and African-American Women with Systemic Lupus Erythematosus PDF